tiprankstipranks
Trending News
More News >

Japan Tissue Engineering Unveils Growth-Oriented Business Plan

Story Highlights
  • Japan Tissue Engineering focuses on regenerative medicine with autologous cultured tissues.
  • The company plans to enhance operations and industry positioning through growth measures.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Japan Tissue Engineering Unveils Growth-Oriented Business Plan

Don’t Miss TipRanks’ Half-Year Sale

An announcement from Japan Tissue Engineering Co., Ltd. ( (JP:7774) ) is now available.

Japan Tissue Engineering Co., Ltd. has announced a business plan outlining measures for growth and addressing market environment and risks. The company is poised to enhance its operations and industry positioning by leveraging its expertise in regenerative medicine, which could have significant implications for stakeholders, including advancements in medical treatments and potential market expansion.

More about Japan Tissue Engineering Co., Ltd.

Japan Tissue Engineering Co., Ltd. operates in the regenerative medicine industry, focusing on the development and commercialization of autologous cultured tissues. Their primary products include JACE, JACEMIN, JACC, NEPIC, and OCURAL, which are regenerative medical products derived from patients’ own tissues. The company also offers LabCyte, a cultured human tissue for research purposes, providing an alternative to animal testing.

Average Trading Volume: 305,795

Technical Sentiment Signal: Buy

Current Market Cap: Yen23.88B

Learn more about 7774 stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1